EGFR
Gli inibitori del recettore del fattore di crescita epidermico (EGFR) sono composti che bloccano la segnalazione dell'EGFR, un recettore spesso sovraespresso in vari tipi di cancro e che svolge un ruolo cruciale nell'angiogenesi. Gli inibitori dell'EGFR sono utilizzati per prevenire la crescita tumorale e le metastasi interrompendo le vie che promuovono la formazione di vasi sanguigni nei tumori. Questi inibitori sono ampiamente utilizzati nella ricerca e nella terapia del cancro. Presso CymitQuimica, offriamo una vasta selezione di inibitori dell'EGFR di alta qualità per supportare la tua ricerca in oncologia e angiogenesi.
Trovati 593 prodotti di "EGFR"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-85
CAS:EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFRFormula:C26H30N8O2Purezza:98%Colore e forma:SolidPeso molecolare:486.57EGFR-IN-30
CAS:EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.Formula:C28H33BrN7O2PColore e forma:SolidPeso molecolare:610.49EGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Formula:C32H28BrF3N6O4SColore e forma:SolidPeso molecolare:729.57BMS-599626 Hydrochloride
CAS:BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.Formula:C27H28ClFN8O3Purezza:99.98%Colore e forma:SolidPeso molecolare:567.01JND3229
CAS:JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Formula:C33H41ClN8O2Purezza:98.75%Colore e forma:SolidPeso molecolare:617.18EGFR-IN-1
CAS:<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Formula:C28H30N6O4Purezza:98%Colore e forma:SolidPeso molecolare:514.58BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formula:C22H25BrN4O2Purezza:99.02%Colore e forma:SolidPeso molecolare:457.36EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formula:C31H34N6O3Colore e forma:SolidPeso molecolare:538.64PAT-505
CAS:PAT-505 is an autologous epidermal growth factor inhibitor.Formula:C23H18ClF2N3O2SPurezza:98.84%Colore e forma:SolidPeso molecolare:473.92HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Formula:C31H29ClFN5O3Purezza:99.91%Colore e forma:SolidPeso molecolare:574.05BPIQ-I
CAS:BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.Formula:C16H12BrN5Colore e forma:SolidPeso molecolare:354.2PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Formula:C19H22ClN7O3Purezza:98%Colore e forma:SolidPeso molecolare:431.88EGFR-IN-33
CAS:EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).Formula:C26H25ClN6O2Colore e forma:SolidPeso molecolare:488.97(Z)-RG-13022
CAS:(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].Formula:C16H14N2O2Colore e forma:SolidPeso molecolare:266.29HER2-IN-5
CAS:HER2-IN-5 is an effective inhibitor of orally active HER-2.Formula:C27H33N7O3Colore e forma:SolidPeso molecolare:503.6Lifirafenib
CAS:Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinantFormula:C25H17F3N4O3Purezza:97.99% - 98%Colore e forma:SolidPeso molecolare:478.42Ref: TM-T22272
1mg35,00€5mg69,00€10mg97,00€25mg190,00€50mgPrezzo su richiesta100mgPrezzo su richiesta1mL*10mM (DMSO)89,00€EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Colore e forma:SolidPeso molecolare:405.62EGFR-IN-36
CAS:EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Formula:C26H25ClN6O2Colore e forma:SolidPeso molecolare:488.97MS 154
CAS:MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.Formula:C46H54ClFN8O8Colore e forma:SolidPeso molecolare:901.42BEBT-109
CAS:BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formula:C27H32N8O3Purezza:97.26%Colore e forma:SolidPeso molecolare:516.6EGFR-IN-29
CAS:EGFR-IN-29 is a potent EGFR inhibitor.Formula:C36H46BrN8O2PColore e forma:SolidPeso molecolare:733.68Labuxtinib
CAS:<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Formula:C20H16FN5O2Purezza:99.77%Colore e forma:SolidPeso molecolare:377.37EGFR/HER2-IN-13
CAS:EGFR/HER2-IN-13 (Compd 38) serves as an inhibitor targeting mutant EGFR/HER2s that show resistance to existing drugs. It is primarily utilized in cancer research.Formula:C27H36N8O3Peso molecolare:520.63Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Formula:C42H51N9O5Colore e forma:SolidPeso molecolare:761.91EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formula:C28H31ClN6O4Purezza:99.16%Colore e forma:SolidPeso molecolare:551.04Ref: TM-T11157L
1mg65,00€5mg150,00€10mg215,00€25mg338,00€50mg452,00€100mg620,00€200mg838,00€1mL*10mM (DMSO)202,00€EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purezza:98.64%Colore e forma:SolidPeso molecolare:499.61BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formula:C24H31N5O4Purezza:96.74%Colore e forma:SolidPeso molecolare:453.53EGFR/ErbB-2 inhibitor-1
CAS:EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.Formula:C23H15ClFN3OS2Purezza:98.93%Colore e forma:SolidPeso molecolare:467.97Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formula:C24H25ClN4O5Purezza:99.81%Colore e forma:SolidPeso molecolare:484.93EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formula:C32H23ClF3N7O4Purezza:99.51%Colore e forma:SolidPeso molecolare:662.02EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formula:C27H25N3O6SColore e forma:SolidPeso molecolare:519.57HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formula:C19H14BrF3N2OColore e forma:SolidPeso molecolare:423.23BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formula:C18H15N3O2Colore e forma:SolidPeso molecolare:305.331D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formula:C25H26Cl2FN7O3Colore e forma:SolidPeso molecolare:562.42EGFR Ligand-Linker Conjugates 1
CAS:EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Formula:C37H47N9O3Colore e forma:SolidPeso molecolare:665.83HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Colore e forma:SolidPeso molecolare:549.53EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formula:C14H11BrN4O2SColore e forma:SolidPeso molecolare:379.23PROTAC Her3-binding moiety 2
CAS:PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Formula:C25H25N7O2Colore e forma:SolidPeso molecolare:455.51LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formula:C21H20ClN3O4Colore e forma:SolidPeso molecolare:413.854EGFR-IN-48
EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.Colore e forma:SolidHER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formula:C20H18N4O3SColore e forma:SolidPeso molecolare:394.447Tesevatinib tosylate
CAS:Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Formula:C31H33Cl2FN4O5SColore e forma:SolidPeso molecolare:663.59EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Colore e forma:SolidPeso molecolare:284.27EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Colore e forma:SolidEGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formula:C26H27ClN6O2Colore e forma:SolidPeso molecolare:490.98Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formula:C32H31ClN6O4Colore e forma:SolidPeso molecolare:599.08EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formula:C13H13N5OColore e forma:SolidPeso molecolare:255.275EG31
CAS:EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formula:C30H13Br2N3O6Colore e forma:SolidPeso molecolare:671.25NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C20H16O7Colore e forma:SolidPeso molecolare:368.34SORT1-IN-5
CAS:SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Formula:C19H31NO6SColore e forma:SolidPeso molecolare:401.52EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Colore e forma:SolidEGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formula:C27H19ClFN3OColore e forma:SolidPeso molecolare:455.91HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formula:C17H18BrN5O2SColore e forma:SolidPeso molecolare:436.33EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Formula:C31H30FN7OColore e forma:SolidPeso molecolare:535.61EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formula:C30H26N8OColore e forma:SolidPeso molecolare:514.58EGFR-IN-149
CAS:EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Formula:C16H15N3OSColore e forma:SolidPeso molecolare:297.375EGFR-IN-132
CAS:EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formula:C27H31N7O3Colore e forma:SolidPeso molecolare:501.58EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formula:C19H21N3O2SColore e forma:SolidPeso molecolare:355.45Si306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formula:C25H26BrClN6OSColore e forma:SolidPeso molecolare:573.94Andamertinib
CAS:Andamertinib is an EGFR inhibitor with antitumor activity.Formula:C31H36N8O3Colore e forma:SolidPeso molecolare:568.669EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formula:C26H28ClN3O4Colore e forma:SolidPeso molecolare:481.97EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Formula:C12H14N4OS2Colore e forma:SolidPeso molecolare:294.4HER2-IN-6
CAS:HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Formula:C26H32N8O3Colore e forma:SolidPeso molecolare:504.58Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formula:C24H24Br2ClN9O3Purezza:99.52%Colore e forma:SolidPeso molecolare:681.77Ref: TM-T13088
1mg140,00€5mg283,00€10mg432,00€25mg707,00€50mg938,00€100mg1.311,00€1mL*10mM (DMSO)437,00€Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formula:C10H8N2OColore e forma:SolidPeso molecolare:172.183Neptinib
CAS:Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.Formula:C22H23ClFN5O2Colore e forma:SolidPeso molecolare:443.90BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formula:C29H33ClN8O4Colore e forma:SolidPeso molecolare:593.08ES-072
CAS:ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.Formula:C25H27F3N8O2Colore e forma:SolidPeso molecolare:528.53HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formula:C28H26F3N7O3Colore e forma:SolidPeso molecolare:565.55EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formula:C16H16N4O2SColore e forma:SolidPeso molecolare:328.39EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Colore e forma:SolidPeso molecolare:489.96EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formula:C27H25ClN2O4Colore e forma:SolidPeso molecolare:476.951EGFR-IN-126
CAS:EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.Formula:C28H28BrFN4O3Colore e forma:SolidPeso molecolare:567.45EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Formula:C33H28N6O3SColore e forma:SolidPeso molecolare:588.68EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formula:C25H24ClN7O2Colore e forma:SolidPeso molecolare:489.96Tyrosine Protein Kinase Substrate
CAS:Tyrosine Protein Kinase Substrate is a polypeptide molecule with the sequence RRLIEDNEYTARG.Formula:C66H109N23O23Peso molecolare:1592.71EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formula:C21H23N3O5Colore e forma:SolidPeso molecolare:397.424EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Formula:C27H31ClN7O3PColore e forma:SolidPeso molecolare:568.01EGFR-IN-23
CAS:EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formula:C36H44BrN10O3PColore e forma:SolidPeso molecolare:775.68JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurezza:98%Colore e forma:SolidPeso molecolare:464.54EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formula:C30H35FN6O3Colore e forma:SolidPeso molecolare:546.64JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formula:C31H29FN4O3SColore e forma:SolidPeso molecolare:556.65EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formula:C32H41BrN9O2PPurezza:95.32% - 99.64%Colore e forma:SolidPeso molecolare:694.6HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Colore e forma:Odour LiquidNimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Colore e forma:LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Colore e forma:Odour LiquidTLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFormula:C16H15N5Colore e forma:Yellow SolidPeso molecolare:277.331Olmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormula:C26H26N6O2SPurezza:99.14%Colore e forma:SolidPeso molecolare:486.59Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Purezza:95%Colore e forma:LiquidRef: TM-T80604
Prodotto fuori produzioneEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formula:C32H41BrN9O2PPurezza:98%Colore e forma:SolidPeso molecolare:694.6Ref: TM-T78788
Prodotto fuori produzioneYK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formula:C27H32N8O2Purezza:98%Colore e forma:SolidPeso molecolare:500.6Ref: TM-T79461
Prodotto fuori produzioneEGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formula:C19H20N4O3Colore e forma:SolidPeso molecolare:352.39Ref: TM-T200157
Prodotto fuori produzioneEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formula:C24H27F3N6OColore e forma:SolidPeso molecolare:472.51Ref: TM-T200485
Prodotto fuori produzione
